The Federal Trade Commission has moved to axe a lawsuit claiming its case against three major US pharmacy benefit managers over rising insulin prices can’t proceed in its administrative court.
Units of
That attack is not “legally viable, much less capable of supporting their request for the extraordinary relief of a preliminary injunction,” the FTC said in a motion filed late Wednesday in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.